Browsing: Wellness Tips

Background: The popularity of GLP-1 receptor agonists (GLP-1 RAs) for weight loss has increased significantly in recent years, raising concerns about self-medication with these medications. Objective: To assess the proportion and identify factors associated with GLP-1 RA use without medical prescription among GLP-1 RA users in Brazil. Methods: This cross-sectional study was conducted through a…

With spring just around the corner, there’s no better time to give your diet a gentle overhaul than right now, in preparation for warmer weather. But where to start?

Scientists might be inching closer to a breakthrough that some of us lazy bums would very much appreciate: a pill that can safely provide the same healthy benefits of exercise

Endocrine Society experts willdiscuss itsbrand-newScientific Statementonresearch in thenew era ofobesity medicinesand how this publication is part of a broader Center on Obesity initiativeduring avirtual news conferenceon September 9.What:Thevirtualnewsconference willcoverthe Society’s:

Eli Lilly LLY remains a dominant player in the GLP-1 market, led by Mounjaro for type II diabetes (T2D) and Zepbound for obesity. The two tirzepatide-based therapies continued to drive Lilly’s top-line performance in the second quarter of 2026. Mounjaro generated $9.94 billion in worldwide revenues, up 91% year over year, while Zepbound sales increased 46%…

Christopher Schwarzenegger is flaunting his new physique in a picture from the famous family’s vacation

WASHINGTON — Chances are you’ve seen the ads promoting cheaper weight-loss shots, no insurance required, delivered straight to your door. They’re everywhere you look right now, from social media to late-night TV

ByRachael O’Connor Newsweek is a Trust Project member See more of our trusted coverage when you search.to see more of our trusted coverage when you search.

AN INDIVIDUAL patient data meta-analysis has revealed that higher BMI significantly reduces the effectiveness of JAK inhibitors in rheumatoid arthritis, with obesity acting as a true modifier of treatment response rather than simply a marker of worse prognosis

The GHA is considering whether to offer oral GLP-1 weight-loss drugs, with the service expected to change significantly within the next decade as new treatments become available, the Director of Public Health, Dr Helen Carter, has said